1

Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial

2

Nathaniel M. Schuster, MD^{1,6*}, Mark S. Wallace, MD^{1,6}, Thomas D. Marcotte, PhD^{2,6}, Dawn C. Buse,
 PhD⁷, Euyhyun Lee, MSc³, Lin Liu, PhD⁴, Michelle Sexton, ND^{5,6}

5

 ¹Center for Pain Medicine, Department of Anesthesiology, ²Department of Psychiatry, ³Altman Clinical and Translational Research Institute, ⁴Department of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health and Human Longevity Science, ⁵Centers for Integrative Health, Department of Family Medicine, ⁶Center for Medicinal Cannabis Research, University of California, San Diego Health
 System, San Diego, CA, ⁷Department of Neurology, Albert Einstein College of Medicine

11 12 Abstract

1314 Background

15 Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment.

However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute
 migraine.

18

19 Methods

20 In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to 4 21 separate migraine attacks. 1 each with vaporized 1) $6\% \Delta 9$ -tetrahydrocannabinol (THC-dominant); 2)

21 Separate migrane attacks, Teach with vaporized 1) 6% Δ9-tetrahydrocannabinol (THC-dominant); 2)
 22 11% cannabidiol (CBD-dominant); 3) 6% THC+11% CBD; and 4) placebo cannabis flower in a

randomized order. Washout period between treated attack was ≥ 1 week. The primary endpoint was pain

relief and secondary endpoints were pain freedom and most bothersome symptom (MBS) freedom, all

25 assessed at 2 hours post-vaporization.

26 27 **Results**

Ninety-two participants were enrolled and randomized, and 247 migraine attacks were treated. THC+CBD was superior to placebo at achieving pain relief (67.2% vs 46.6%, Odds Ratio [95% Confidence Interval] 2.85 [1.22, 6.65], p=0.016), pain freedom (34.5% vs. 15.5%, 3.30 [1.24, 8.80], p=0.017) and MBS freedom (60.3% vs. 34.5%, 3.32 [1.45, 7.64], p=0.005) at 2 hours, as well as sustained pain freedom at 24 hours and sustained MBS freedom at 24 and 48 hours. THC-dominant was superior to placebo for pain relief (68.9% vs. 46.6%, 3.14 [1.35, 7.30], p=0.008) but not pain freedom or MBS freedom at 2 hours. CBD-dominant was not superior to placebo for pain relief, pain freedom or MBS freedom at 2 hours.

There were no serious adverse events.

37 Conclusions

Acute migraine treatment with 6% THC+11% CBD was superior to placebo at 2 hours post-treatment with sustained benefits at 24 and 48 hours.

- 39 sustained benefits at 24 an40
- 41 Trial Registration Number: NCT04360044
- 42
- 43 *Corresponding author:
- 44 Nathaniel M. Schuster, MD
- 45 UC San Diego Center for Pain Medicine
- 46 9400 Campus Point Drive, Suite 1-300
- 47 La Jolla, CA 92037
- 48 Tel: 858-657-7072
- 49 Fax: 858-249-1239
- 50 Email: <u>nmschuster@health.ucsd.edu</u>
- 51
- 52
- 53

- 1 2 **Disclosures:**
- NMS has received research funding from Migraine Research Foundation, Novaremed, UCSD Academic
- 3 Senate, UCSD Department of Anesthesiology RAG, and NIH CTSA Grant UL1TR000100 and has
- 4 consulted for Eli Lilly & Co., Averitas, Syneos, Schedule 1 Therapeutics, Vectura Fertin, and ShiraTronics.
- He serves on the editorial board of Pain Medicine (Oxford University Press). DCB has been a consultant
- 5 6 for Abbvie, Amgen, Biohaven, Lilly, Lundbeck, Teva, Theranica. She has received grant support from the
- 7 US Food and Drug Association and National Headache Foundation. She is an editor for Current Pain
- 8 and Headache Reports. MSW, TM, EL, LL and MS have no disclosures to report.

1 Manuscript Text

2

3 Introduction

4 Migraine is the second leading cause of years lived with disability worldwide. It affects over a 5 billion people worldwide, including 38 million Americans¹. Migraine treatments are classified for acute 6 and/or preventive use². Nearly everyone with migraine uses acute treatments for migraine attacks. 7 However, rates of treatment optimization with traditional acute therapies are relatively low and rates of 8 discontinuation are high^{3,4}. There is significant interest in and use of cannabinoids for acute migraine 9 treatment. Migraine is among the most common medicinal uses of cannabinoids, with 35.5% of 1,429 10 medical cannabis users reporting use for headache/migraine; inhalation was the most common route of 11 administration (81.4%)⁵.

12

More than 125 identified phytocannabinoids are naturally found in the cannabis plant, including Δ 9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Although the US Food and Drug Administration (FDA) has approved cannabinoid-based medications for specific conditions, none have been approved for migraine. At the time of this writing, THC was legal for medical and/or recreational use in 38 US states and the District of Columbia. Since 2018, hemp-derived CBD (<0.3% THC) is not a controlled substance in the US⁶.

19

20 Patients often ask healthcare professionals about cannabinoids for migraine, but data to inform 21 medical advice is lacking⁷. Preclinical evidence suggests that cannabinoids may have effects on migraine 22 pathogenesis through mechanisms including inhibiting calcitonin gene-related peptide (CGRP) release, 23 inhibiting CGRP-induced nitric oxide release, inhibiting trigeminovascular neurons, and inhibiting cortical 24 spreading depression, and surveys and retrospective studies suggest that cannabinoids may have benefit 25 as acute and/or preventive treatments for migraine^{8–20}. However the efficacy of cannabis for acute 26 treatment of migraine has not been studied via a randomized, controlled trial (RCT)^{10,12,21}. Therefore, this 27 RCT was conducted to assess the efficacy of vaporized cannabis against placebo cannabis.

1 Methods

- 2 Trial Design
- 3 This randomized, double-blind, placebo-controlled, crossover trial was conducted at the University of
- 4 California, San Diego (UCSD). The study was approved by the UCSD Institutional Review Board (IRB
- 5 #181944) and the US FDA. The study was prospectively registered, and full protocol is available, at
- 6 ClinicalTrials.gov (NCT04360044). The authors take full responsibility for the data and the accuracy and
- 7 integrity of the publication. No writing assistance was provided by outside parties. The study was
- 8 performed in accordance with the principles of the Declaration of Helsinki. All participants provided written
- 9 informed consent prior to enrollment.
- 10

11 Sample Size

12 Sample size was determined based on our primary outcome of pain relief at 2 hours, assuming a

13 response of 68% for treatment and 45% for placebo as seen in an intranasal sumatriptan RCT²². This

14 effect size required 72 participants to detect a significant difference with 80%. Assuming a 20% dropout

15 rate, we planned to enroll 90 participants.

16

17 Study Drug

Cannabis flower was obtained from the National Institute on Drug Abuse (NIDA) Drug Supply Program
(DSP) and consisted of 4 different treatments. The most closely matched batches available from the NIDA
DSP at study initiation were selected. They were: 1) 5.62% THC+0.03% CBD (referred to in this study as
6% THC or THC-dominant); 2) 11.27% CBD+0.35% CBD (referred to as 11% CBD or CBD-dominant); 3)
6.16% THC + 10.77% CBD (referred to as 6% THC+11% CBD or THC+CBD); and 4) placebo flower
(<0.025% THC + 0.14% CBD). All treatments contained <1% minor cannabinoids and were devoid of
terpenes. The studied THC potency was based on previous pain studies²³⁻²⁵.

25

26 Participants

27 Key inclusion criteria were: ages 21-65; migraine according to International Classification of Headache

28 Disorders, 3rd edition (ICHD-3) criteria²⁶; 2-23 headache days and 2-23 migraine days per month; agree

- 1 not to use cannabis (outside of the study drug), opioids or barbiturates. Key exclusion criteria were:
- 2 screening visit urine drug test positive for THC, barbiturates, opioids, oxycodone, or methadone;
- 3 pregnant; breastfeeding; known cognitive impairment; current moderate-severe or severe depression;
- 4 history of bipolar disorder, schizophrenia, or psychosis; history of substance use disorder; and active
- 5 pulmonary disease or other severe medical illnesses at the discretion of the researchers. Inclusion criteria
- 6 initially required THC use Table 1: Characteristics of Patient Population 7 within the prior 2 years; this Characteristic All Patients (n=92) Age- median years (Quartiles 1-3) 41 (34-54) Birth Sex- no. (%) 8 was removed March 18, Female 76 (82.6%) Male 16 (17.4%) Gender Identity-no. (%) 9 2021 due to slow Female sex 77 (83.7%) 15 (16.3%) Male sex 10 recruitment and no serious BMI- median (Quartiles 1-3) 26.0 (22.8-32.9) Ethnicity Hispanic or Latino 15 (16.3%) 11 adverse events at that time. 77 (83.7%) Not Hispanic or Latino Race or ethnic group-no.(%) 71 (77.2%) White 12 Full criteria are available at Black 8 (8.9%) Asian-American 7 (7.8%) Mixed/Other 2 (2.2%) 13 ClinicalTrials.gov. Middle Eastern 1 (1.1%) Pacific Islander 1 (1.1%) 14 Declined to state 2 (2.2%) Primary language- no. (%) English 83 (90.2%) 15 Participants agreed not to 6 (6.5%) Spanish Other 3 (3.3%) Migraine history 16 use any other acute Age at onset- median years (Quartiles 1-3) 20 (14-28) Headache Days per month- median (Quartiles 1-3) 15 (8-16) 17 Migraine Days per month- median (Quartiles 1-3) 6 (4-10) migraine treatments prior to Chronic Migraine*- no. (%) 25/91 (27.5%) Most bothersome symptom, treated attack 18 or within 2 hours following 148 (63.2%) Photophobia 38 (16.2%) Phonophobia Nausea 48 (20.5%) 19 study drug administration. Last Cannabis Use Never 33 (35.9%) More than 1 year ago 19 (20.7%) 20 6 months-1 year ago 7 (7.6%) 19 (20.7%) 1 month-6 months ago 21 Enrollment 2 weeks-1 month ago 5 (5.4%) Last 2 weeks 4 (4.3%) Incomplete Data 5 (5.4%) 22 Participants were enrolled at * Chronic Migraine: At least 15 headache days and at least 8 migraine days per month 23 UCSD November 20, 2020-November 4, 2022 with follow-up completed February 23, 2023. A headache
- 24 neurologist experienced in ICHD-3 criteria (NMS) confirmed participant eligibility.

- 26 After written informed consent, baseline characteristics were captured using REDCap²⁷. Then participants
- 27 were trained in the Foltin Uniform Puff Procedure (FUPP), a validated cannabis vaporization procedure,

and a smartphone application was installed on participants' smartphones to guide participants through the
 study and collect data²⁸.

3

4 Randomization

5 A research pharmacist randomized participants to receive the 4 different treatments using simple 1:1:1:1

6 assignment (24 possible orders) using Microsoft Excel's random number function.

7

8 Blinding

9 Participants, research coordinators, investigators, and statisticians were blinded until after the initial

10 statistical analysis was completed; only the research pharmacists were unblinded during the study. The

11 four treatments were prepared into identical Storz & Bickel Filling Set vaporization capsules by a research

12 pharmacist and placed into sealed bags. Labels were affixed to the sealed bags stating the order in which

13 the participant would use the four treatments ("Migraine 1" through "Migraine 4"). The key linking the

14 treatments to their identifying number was stored on a password-protected computer in the locked

15 pharmacy available only to the research pharmacists.

16

Participant blinding was promoted by using placebo cannabis flower from which the THC and CBD had been extracted via a chemical process by the NIDA DSP and by framing, including educating patients that they might experience a "placebo high" from the CBD-dominant and placebo treatments and that they might not experience a "high" from the THC-dominant and THC+CBD treatments as the study potencies were lower than "recreational" potencies. Each attack, after answering 2-hour efficacy and safety questions, participants were asked which treatment they thought they received.

23

24 Treatments

Upon each migraine attack onset, the participant accessed the smartphone application. If ≥7 days had
elapsed since the prior cannabis administration (ensuring ≥7 days washout period between cannabis
administrations) the application asked the participant questions to establish whether the attack met
treatment criteria of: 1) headache <4 hours from onset, 2) headache pain moderate or severe in intensity,

3) associated with photophobia and phonophobia and/or with nausea, 4) no acute treatments used since
attack onset. If the attack met all criteria, the application instructed the participant to vaporize study
cannabis at 180° Celsius and guided the participant through the timed FUPP to standardize vaporization
procedure across treated attacks and across participants. FUPP consists of five seconds of inhalation,
followed by a ten second breath hold, exhalation, and 45 second waiting period before repeating the
process²⁸. Each attack, participants performed the FUPP 4 times under continuous application guidance.
The application pushed surveys at 1, 2, 24 and 48 hours.

8

9 Outcomes


10 Outcomes were based on International Headache Society (IHS) guidelines²⁹. Primary outcome was pain 11 relief at 2 hours post-vaporization²⁹ based on the limited supporting evidence at study initiation¹⁸. 12 Secondary outcomes were 2-hour pain freedom and 2-hour most bothersome symptom (MBS) freedom²⁹. 13 Other outcomes included freedom from pain, photophobia, phonophobia, nausea, and vomiting, and 14 rescue medication use, with data collected at 1, 2, 24 and 48 hours²⁹. Pain at time 0 and each 15 subsequent timepoint was reported as none, mild, moderate or severe²⁹. Pain relief was defined as reduction of pain from moderate or severe to mild or none²⁹. Pain freedom was defined as absence of 16 17 pain. Sustained pain freedom was defined as pain freedom at 2 hours without return of pain or rescue 18 medication use²⁹. MBS (selected from photophobia, phonophobia, or nausea) was identified by the 19 participant during each attack prior to vaporization; MBS freedom was defined as absence of the MBS at 20 each subsequent timepoint. Sustained MBS freedom was defined as MBS freedom at 2 hours without 21 return of the MBS or rescue medication use at each subsequent timepoint ²⁹. All outcomes presented 22 here were prospectively registered (NCT04360044).


23

24 Analyses

The intention-to-treat (ITT) analysis analyzed all treated migraine attacks, counting treated attacks without recorded 2-hour data as treatment failures as per IHS guidelines²⁹. The modified intention-to-treat analysis (mITT) only analyzed attacks with recorded 2-hour data. During the trial, some subjects filled out surveys early or late. We performed a sensitivity analysis analyzing only attacks with 2-hour data time


1 stamped 1.5-3 hours post-vaporization, a time window selected to retain as much data as possible 2 without increasing possible exposure to retention bias^{30–32}. As per IHS guidelines, for all analyses, attacks 3 for which the participant used rescue medication before the 2-hour assessment were counted as 4 treatment failures²⁹. The differences in pain relief, pain freedom, and MBS freedom among the four 5 treatments were assessed using a generalized linear mixed effects model with a logit link for binary 6 outcomes. A random intercept structure was included to account for the cluster effect of subjects going 7 through the same trial multiple times. Secondary and other analyses at 1, 24, and 48 hours were 8 conducted using similar methods. Statistical analyses were performed using RStudio, version 4.1.2 (R 9 Foundation). All tests were two-sided with p<0.05 indicating statistical significance.





23 The mITT analysis included 234 attacks from 71 patients. The sensitivity analysis included 202 attacks

- 1 from 70 patients (Figure 1). The results
- 2 were similar across the ITT, mITT, and
- 3 sensitivity analyses for the primary
- 4 endpoint of 2-hour pain relief and
- 5 secondary endpoints of 2-hour pain
- 6 freedom and 2-hour MBS freedom.
- 7 Where not otherwise specified, mITT
- 8 results are reported as they neither used
- 9 imputed data (as in the ITT) nor
- 10 excluded data (as in the sensitivity
- 11 analysis).
- 12
- 13 For the primary outcome of 2-hour pain
- 14 relief, THC+CBD and THC-dominant
- 15 were superior to placebo but CBD-
- 16 dominant was not in all 3 analyses. In
- 17 the ITT analysis, 2-hour pain relief
- 18 responder rates were 63.9% with
- 19 THC+CBD, 67.7% with THC-dominant,
- 20 50% with CBD-dominant, and 42.2%
- 21 with placebo. In the mITT analysis, 2-
- 22 hour pain relief was achieved by 67.2%
- 23 with THC+CBD (OR [95%] 2.85 [1.22-
- 24 6.65], p=0.016), 68.9% with THC-
- 25 dominant (3.140 [1.35-7.30], p=0.008),
- 26 52.6% with CBD-dominant (p>0.05), and
- 27 46.6% with placebo (Figures 2 and 3). In
- 28 the sensitivity analysis; 2-hour pain relief



2B) Pain Freedom rates at 1h and 2h and Sustained Pain Freedom rates at 24h and 48h 2C) Most Bothersome Symptom (MBS) Freedom rates at 1h

and 2h and Sustained MBS Freedom rates at 24h and 48h (* p<0.05)

1 responder rates were 64.0% with THC+CBD, 70.0% with THC-dominant, 53.1% with CBD-dominant, and

2 45.3% with placebo.

3

4 For the secondary outcomes, THC+CBD was superior to placebo in all 3 analyses for 2-hour pain

5 freedom (mITT 34.5% vs. 15.5%, 3.30 [1.24-8.80], p=0.017) and 2-hour MBS freedom (mITT 60.3% vs.

6 34.5%, 3.32 [1.45-7.64], p=0.005) but THC-dominant and CBD-dominant were not (Figures 2 and 3).

7	Adjusting for	Figure 3: Forest Plots o	of Efficacy D	ata		
8	treatment		CBD Dominant	Placebo n (%)		OR (95% Cl)
9	session number	Pain relief, 2h Pain freedom, 2h MBS freedom, 2h Pain relief, 1h Sustained pain freedom, 2–24h Sustained pain freedom 2–48h	30 (52.6%) 13 (22.8%) 23 (40.4%) 33 (58.9%) 8 (16.0%) 6 (13.0%)	27 (46.6%) 9 (15.5%) 20 (34.5%) 22 (36.7%) 6 (10.7%) 5 (10.2%)		1.355 (0.602, 3.049) 1.666 (0.604, 4.595) 1.311 (0.579, 2.966) 3.200 (1.309, 7.824) 1.598 (0.489, 5.225) 1.293 (0.351, 4.763)
10	did not affect the	Sustained MBS freedom, 2–24h Sustained MBS freedom, 2–48h Freedom from photophobia, 2h Freedom from phonophobia, 2h	15 (30.0%) 13 (28.3%) 24 (42.1%) 36 (63.2%)	14 (25.0%) 9 (18.4%) 22 (37.9%) 30 (51.7%)		1.298 (0.496, 3.395) 1.916 (0.682, 5.386) 1.198 (0.498, 2.878) 1.797 (0.745, 4.334)
11	results of the	Freedom from nausea, 2h Freedom from vomiting, 0–48h No use of rescue medication through 48h	47 (82.5%) 44 (95.7%) 30 (65.2%)	41 (70.7%) 47 (95.9%) 25 (51.0%)		2.216 (0.810, 6.059) 1.348 (0.056, 32.398) 2.226 (0.810, 6.120)
12	primary or	Pain relief, 2h	THC Dominant n (%) 42 (68.9%)	Placebo n (%) 27 (46.6%)		OR (95% Cl) 3.140 (1.352, 7.295)
13	secondary	Pain freedom, 2h MBS freedom, 2h Pain relief, 1h Sustained pain freedom, 2–24h Sustained pain freedom 2–48h	17 (27.9%) 29 (47.5%) 38 (65.5%) 11 (19.6%) 7 (13.5%)	9 (15.5%) 20 (34.5%) 22 (36.7%) 6 (10.7%) 5 (10.2%)		2.377 (0.890, 6.348) 1.893 (0.848, 4.225) 4.719 (1.886, 11.808) 2.123 (0.689, 6.538) 1.396 (0.396, 4.918)
14	outcomes.	Sustained MBS freedom, 2–24h Sustained MBS freedom, 2–48h Freedom from photophobia, 2h Freedom from phonophobia, 2h Freedom from nausea, 2h	21 (37.5%) 14 (26.9%) 32 (52.5%) 37 (60.7%) 51 (83.6%)	14 (25.0%) 9 (18.4%) 22 (37.9%) 30 (51.7%) 41 (70.7%)		1.895 (0.757, 4.745) 1.764 (0.644, 4.831) 2.392 (1.000, 5.721) 1.630 (0.692, 3.843) 2.379 (0.879, 6.443)
15		Freedom from vomiting, 0–48h No use of rescue medication through 48h	49 (94.2%) 37 (71.2%)	47 (95.9%) 25 (51.0%)	0007 0.002 1.105 0.200 1.00 2.00 4.00 8.00	0.586 (0.034, 10.020) 3.239 (1.184, 8.862)
16	THC+CBD was	Pain relief, 2h Pain freedom, 2h MBS freedom. 2h	THC/CBD Mix n (%) 39 (67.2%) 20 (34.5%) 35 (60.3%)	Placebo n (%) 27 (46.6%) 9 (15.5%) 20 (34.5%)		OR (95% CI) 2.846 (1.218, 6.652) 3.295 (1.235, 8.795) 3.322 (1.445, 7.637)
17	superior to	Pain relief, 1h Sustained pain freedom, 2–24h Sustained pain freedom 2–48h Sustained MBS freedom, 2–24h	30 (53.6%) 14 (28.0%) 11 (22.9%) 23 (46.0%)	22 (36.7%) 6 (10.7%) 5 (10.2%) 14 (25.0%)		2.562 (1.051, 6.248) 3.454 (1.137, 10.497) 2.768 (0.840, 9.124) 2.828 (1.101, 7.262)
18	placebo at 2	Sustained MBS freedom, 2–48h Freedom from photophobia, 2h Freedom from phonophobia, 2h Freedom from nausea, 2h Freedom from vomiting, 0–48h	19 (39.6%) 33 (56.9%) 43 (74.1%) 44 (75.9%) 47 (97.9%)	9 (18.4%) 22 (37.9%) 30 (51.7%) 41 (70.7%) 47 (95.9%)		3.394 (1.237, 9.317) 2.723 (1.119, 6.623) 3.723 (1.450, 9.557) 1.291 (0.500, 3.337) 8.150 (0.193, 344.322)
19	hours with	No use of rescue medication through 48h	30 (62.5%)	25 (51.0%)	4.29 6.89 18 28 48 68 968 323 644 3268 2269	2.148 (0.781, 5.906)

20 regards to freedom from photophobia and phonophobia but not nausea or vomiting, while THC-dominant

- 21 and CBD-dominant were not superior to placebo for any of these (Figure 3).
- 22

23 At 1 hour, pain relief responder rate for THC+CBD (53.6%, 2.56 [1.05-6.25], p=0.039), THC-dominant

24 (65.5%, 4.72 [1.89-11.81], p<0.001), and CBD-dominant (58.9%, 3.20 [1.31-7.82], p=0.011) were all

25 superior to 36.7% responder rate with placebo. 1-hour pain freedom was superior only for THC-dominant

26 vs. placebo (17.2% vs 5.0%, 4.90 [1.12-21.34], p=0.034), and 1-hour MBS freedom was superior for

27 THC-dominant (37.9%, 2.68 [1.06-6.79], p=0.038) and CBD-dominant (41.1%, 3.10 [1.21-7.91], p=0.018)

28 but not for THC+CBD (33.9% vs., 2.19 [0.85-5.64], p=0.103) vs. placebo (21.7%).

T								
2	Only THC+CBD had superior sustained benefit versus placebo (Figures 2 and 3). THC+CBD was							
3	superior to placebo regarding 24-hour sustained pain freedom (28.0% vs. 10.7%, 3.45 [1.14-10.50],							
4	p=0.029), 24-hour sustained MBS fi	reedom (46.0% vs.	25.0%,	2.83 [1.1	0-7.26],	p=0.031), ar	าd 48-hour	
5	sustained MBS freedom (39.6% vs. 18.4%, 3.39 [1.24-9.32], p=0.018) but the difference for 48-hour							
6	sustained pain freedom was non-significant (22.9% vs 10.2%, 2.77 [0.84-9.12], p=0.094). THC-dominant							
7	and CBD-dominant were not differe	nt from placebo reg	jarding 2	24- or 48	-hour su	stained pain	freedom or	•
8	sustained MBS freedom.	Table 2: Adverse Events						
9	Adverse events are reported in	2A	Placebo	CBD	THC+CBD	тнс		
10	Table 2. Mean subjective	1 Hour (N) Sleepiness	N=60 16 (26.7%)	N=56 21 (37.5%)	N=56 25 (44.6%)	N=58 24 (41.4%)		
11	highness on a 0-10 scale at 1	Euphoria Cognitive Impairment	4 (7%) 4 (7%)	5 (8.9%) 8 (14.3%)	16 (28.6%) 12 (21.4%)	21 (36.2%) 20 (34.5%)		
12	hour was greatest with THC-	Highness (0-10) Mean (SD) 2 Hours (N)	0.6 (1.2) N=58	1.5 (2.0) N=57	2.4 (2.5) N=58	3.5 (3.0) N=61		
13	dominant at 3.5 (SD 3.0),	Sleepiness Euphoria	22 (37.9%) 1 (1.7%)	29 (50.9%) 2 (3.5%)	18 (31.0%) 6 (10.3%)	26 (42.6%) 17 (27.9%)		
14	followed by 2.4 (SD 2.5) with	Cognitive Impairment Highness (0-10) Mean (SD)	3 (5.2%) 0.4 (1.0)	4 (7.0%) 0.9 (1.6)	7 (12.1%) 1.3 (1.9)	17 (26.2%) 2.4 (2.8)		
15	THC+CBD, 1.5 (SD 2.0) with	2B	ioreo quente	Placebo	CBD 11/56 (19.6%	THC+CBD	THC	
		Participants reporting any adv Adverse events reported at 1		3/60 (5.0%) 0	7) 11/56 (19.6%)	18/58 (31.0%) 13	
16	CBD-dominant, and 0.6 (SD	Sedation		0	2	3	0	
. –		Slowness		0	1	0	4	
17	1.20) with placebo. At 2 hours	Paresthesias		0	0	1	2	
10		Throat irritation		0	3	2	0	
18	subjective highness was	Increased appetite		0	2	1	1	
10		Impaired cognition		0	0	2	1	
19	reduced to 2.4 (SD 2.8) with	Very high		0	0	2	1	

- 20 THC-dominant, 1.3 (SD 1.9)
- 21 with THC+CBD, 0.9 (SD 1.6)
- with CBD-dominant, and 0.4
- 23 (SD 1.0) with placebo. THC-
- 24 dominant had the greatest
- 25 euphoria, cognitive impairment
- and subjective highness,
- 27 followed by THC+CBD, then

Table 2A) Rates of queried adverse events Table 2B) Categorized free response adverse events

Impaired focus

participants at 2 hours Sedation

Impaired focus

Throat irritation

Increased appetite

Impaired cognition

Slowness

Dizziness

Dry mouth

Very high

Paresthesias

Adverse events reported by ≥1% of

Dizziness

Dry mouth

3/58 (5.2%)

4/57 (7.0%)

4/58 (6.9%)

11/61 (18.0%)

CBD-dominant, and least with placebo. Across all 4 treatments there were no serious adverse events
 (Table 2).

3

4	Regarding blinding, correct identification of treatment at 2 hours was 29.3% (17/58) with placebo, 10.5%
5	(6/57) with CBD-dominant, 13.1% (8/61) with THC-dominant, and 20.7% (12/58) with THC+CBD.
6	Participants selected "unknown" 24% of the time; 28% of the time with placebo, 26% with CBD-dominant,
7	22% with THC+ CBD, and 21% with THC-dominant. While 50% of treatments could have contained THC
8	(THC-dominant or THC+CBD) and in this study 50.9% (119/234) treatments contained THC, participants
9	correctly identified that a treatment contained THC (selecting "THC-dominant", "THC+CBD", or "Either
10	THC-dominant or THC+CBD") slightly less than expected by chance, 46.6% (27/58) of the time after
11	THC+CBD treatment and 49.2% (30/61) after THC-dominant treatment. Meanwhile, 32% of participants
12	selected a THC-containing answer after treatment with CBD-dominant and 14% after treatment with
13	placebo.
14	
15	Discussion
16	
17	In this study, the first randomized, double-blind, placebo-controlled trial testing the efficacy of
18	cannabinoids for acute migraine, 6% THC+11% CBD was superior to placebo for pain relief, pain freedom
19	and MBS at 2 hours, as well as freedom from photophobia and phonophobia at 2 hours and 24-hour
20	sustained pain freedom and sustained MBS freedom and 48-hour sustained MBS freedom.
21	
22	THC potencies (6%) were lower than typical with cannabis available via American dispensaries and
23	subjective highness (2.4 out of 10 at 1 hour) with THC+CBD was roughly half of that reported by research
24	participants using cannabis ad lib ³³ , bolstering evidence that higher potencies and titrating to highness
25	are unnecessary for medicinal benefit. THC+CBD had less euphoria, subjective cognitive impairment, and
26	subjective highness than THC-dominant. CBD is reported to be a non-competitive, negative allosteric
27	modulator of the CB1 receptor, by which CBD may decrease the psychoactive effects of THC ^{34–36} .

1	The blinding data, as well as THC+CBD having more acute migraine benefit with less psychoactive			
2	effects as compared to THC-dominant, suggests that this study's findings are not explainable by			
3	expectation effects or unmasking due to psychoactive side effects.			
4				
5	THC+CBD's efficacy for reducing photophobia and phonophobia but not nausea in this study may be in			
6	part explainable by lower time 0 rates of nausea (59.9%) than photophobia (91.9%) and phonophobia			
7	(87.0%) in this study. That THC+CBD reduced photophobia and phonophobia but not nausea or vomiting			
8	in this study demonstrates that THC+CBD's effects on MBS are not explainable by THC's established			
9	antiemetic effects ³⁷ (Figure 3).			
10				
11	Strengths of the study include generalizability by enrolling patients with both episodic (72.5%) and chronic			
12	(27.5%) migraine to best reflect the larger patient population; historically most acute migraine studies			
13	have excluded patients with chronic migraine. Limitations of this study include that the study only			
14	examined THC and CBD; minor cannabinoids and terpenes were not studied. It also only studied single			
15	potencies of THC of CBD and a single THC:CBD ratio.			
16				
17	Typical of acute migraine RCTs, this study did not assess repeated administrations or regular, long-term			
18	treatments to assess possible risks (including rates of development of medication overuse headache and			
19	cannabis use disorder) or benefits (including possible migraine preventive effects) ^{29,38} . A small body of			
20	literature shows improvements on patient reported outcomes when using cannabis-based medicinal			
21	products on a regular, longer term or preventive basis ^{20,39} . More research is needed to evaluate repeated			
22	administrations and regular, long-term use of cannabinoids for migraine.			
23				
24	Conclusion			
25				
26	In this first randomized, double-blind, placebo-controlled trial testing the efficacy of cannabinoids for the			
27	acute treatment of migraine, vaporized 6% THC+11% CBD cannabis flower was superior to placebo for			
28	pain relief, pain freedom, and MBS freedom at 2 hours as well as 24-hour sustained pain freedom and			

- sustained MBS freedom and 48-hour sustained MBS freedom. Future research should include
 multicenter studies and long-term studies of benefits and risks with repeated use.
- 3

4 Acknowledgements

5 This study was sponsored by the Migraine Research Foundation, now administered by Hartford 6 HealthCare. The project described was partially supported by the UCSD Academic Senate and the 7 National Institutes of Health, Grant UL1TR001442. The content is solely the responsibility of the authors 8 and does not necessarily represent the official views of the NIH. Study drug was provided by the National 9 Institute on Drug Abuse Drug Supply Program. The authors thank the National Institute on Drug Abuse 10 Drug Supply Program and the National Center for Natural Products Research at the University of 11 Mississippi School of Pharmacy. Vaporizers were donated by Storz & Bickel GmbH & Co. KG, which did 12 not provide any financial support of this study and was not involved in the design or conduct of the study 13 or manuscript preparation. Thanks to Dr. Brooke Towne, MD, Phirum Nguyen, Gayle Dizon, Jay Patel, 14 Brett Taylor, and Megan Sweeney for assistance with conducting this study. Thank you to all the 15 participants who volunteered for this study. 16

17 References

- Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204
 countries and territories, 1990 to 2019. *Pain*. 2022;163(2):E293-E309.
- 20 doi:10.1097/J.PAIN.00000000002275
- Ailani J, Burch RC, Matthew |, Robbins S. The American Headache Society Consensus
 Statement: Update on integrating new migraine treatments into clinical practice. *Headache*.
- 23 2021;61:1021-1039. doi:10.1111/head.14153
- Serrano D, Buse DC, Manack Adams A, Reed ML, Lipton RB. Acute treatment optimization in
 episodic and chronic migraine: results of the American Migraine Prevalence and Prevention
- 26 (AMPP) Study. *Headache*. 2015;55(4):502-518. doi:10.1111/HEAD.12553
- 27 4. Holland S, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB. Rates and reasons for
- 28 discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine

	Prevalence and Prevention (AMPP) study. J Neurol Sci. 2013;326(1-2):10-17.
	doi:10.1016/J.JNS.2012.12.020
5.	Sexton M, Cuttler C, Finnell JS, Mischley LK. A Cross-Sectional Survey of Medical Cannabis
	Users: Patterns of Use and Perceived Efficacy. Cannabis Cannabinoid Res. 2016;1(1):131-138.
	doi:10.1089/can.2016.0007
6.	Gorelick DA. Cannabis-Related Disorders and Toxic Effects. Hardin CC, ed. N Engl J Med.
	2023;389(24):2267-2275. doi:10.1056/NEJMra2212152
7.	Poudel S, Quinonez J, Choudhari J, et al. Medical Cannabis, Headaches, and Migraines: A
	Review of the Current Literature. Cureus. 2021;13(8). doi:10.7759/CUREUS.17407
8.	Akerman S, Kaube H, Goadsby PJ. Anandamide is able to inhibit trigeminal neurons using an in
	vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004;309(1):56-63.
	doi:10.1124/jpet.103.059808\rjpet.103.059808 [pii]
9.	Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits
	trigeminovascular neurons. J Pharmacol Exp Ther. 2007;320(1):64-71.
	doi:10.1124/jpet.106.106971
10.	Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic
	implications in medicine and headache: What a long strange trip it's been Headache.
	2015;55(6):885-916. doi:10.1111/head.12570
11.	Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and
	Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis
	Science. Headache. 2018;58(7):1139-1186. doi:10.1111/head.13345
12.	McGeeney BE. Cannabinoids and hallucinogens for headache. Headache. 2013;53(3):447-458.
	doi:10.1111/head.12025
13.	Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Endocannabinoids in the Brainstem
	Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and "Triptan" Receptors:
	Implications in Migraine. J Neurosci. 2013;33(37):14869-14877. doi:10.1523/JNEUROSCI.0943-
	13.2013
14.	Kazemi H, Rahgozar M, Speckmann E-J, Gorji A. Effect of cannabinoid receptor activation on
	 6. 7. 8. 9. 10. 11. 12. 13.

1 spreading depression. *Iran J Basic Med Sci.* 2012;15(4):926-936.

- http://www.ncbi.nlm.nih.gov/pubmed/23493641%5Cnhttp://www.pubmedcentral.nih.gov/articlerend
 er.fcgi?artid=PMC3586901.
- 4 15. Aviram J, Vysotski Y, Berman P, Lewitus GM, Eisenberg E, Meiri D. Migraine Frequency
- 5 Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study. *Brain Sci.*
- 6 2020;10(6):1-15. doi:10.3390/BRAINSCI10060360
- 7 16. Stith S, Diviant J, Brockelman F, et al. Alleviative effects of Cannabis flower on migraine and
 8 headache. *J Integr Med.* 2020;18(5):416-424. doi:10.1016/J.JOIM.2020.07.004
- 9 17. Baraldi C, Lo Castro F, Negro A, et al. Oral Cannabinoid Preparations for the Treatment of
- 10 Chronic Migraine: A Retrospective Study. *Pain Med.* 2022;23(2):396-402.
- 11 doi:10.1093/pm/pnab245
- Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of Medical Marijuana on Migraine
 Headache Frequency in an Adult Population. *Pharmacotherapy*. 2016;36(5):505-510.
- 14 doi:10.1002/phar.1673
- Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects of Cannabis on
 Headache and Migraine. *J pain*. 2020;21(5-6):722-730. doi:10.1016/j.jpain.2019.11.001
- 17 20. Nicholas M, Erridge S, Bapir L, et al. UK medical cannabis registry: assessment of clinical
- 18 outcomes in patients with headache disorders. *Expert Rev Neurother*. 2023;23(1):85-96.
- 19 doi:10.1080/14737175.2023.2174017
- 20 21. Lochte BC, Beletsky A, Samuel NK, Grant I. The Use of Cannabis for Headache Disorders.
- 21 *Cannabis Cannabinoid Res.* 2017;2(1):61-71. doi:10.1089/can.2016.0033
- 22 22. Cady RK, McAllister PJ, Spierings EL, et al. A Randomized, Double-Blind, Placebo-Controlled
- 23 Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of
- Acute Migraine (The TARGET Study). *Headache*. 2015;55(1):88-100. doi:10.1111/head.12472
- Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent Effects of Smoked Cannabis on
 Capsaicin- induced Pain and Hyperalgesia in Healthy Volunteers. *Anesthesiology*.

27 2007;107(5):785-796.

28 24. Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of Inhaled Cannabis on

1		Painful Diabetic Neuropathy. <i>J Pain</i> . 2015;16(7):616-627. doi:10.1016/j.jpain.2015.03.008
2	25.	Wallace MS, Marcotte TD, Atkinson JH, Padovano HT, Bonn-Miller M. A Secondary Analysis from
3		a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in
4		Painful Diabetic Peripheral Neuropathy. J pain. 2020;21(11-12):1175-1186.
5		doi:10.1016/j.jpain.2020.03.003
6	26.	Headache Classification Committee of the International Headache Society. The International
7		Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018.
8		doi:10.1177/0333102417738202
9	27.	Obeid JS, McGraw CA, Minor BL, et al. Procurement of shared data instruments for Research
10		Electronic Data Capture (REDCap). J Biomed Inform. 2013;46(2):259-265.
11		doi:10.1016/J.JBI.2012.10.006
12	28.	Foltin RW, Brady J V., Fischman MW. Behavioral analysis of marijuana effects on food intake in
13		humans. Pharmacol Biochem Behav. 1986;25(3):577-582. doi:10.1016/0091-3057(86)90144-9
14	29.	Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for
15		controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia.
16		2019;39(6):687-710. doi:10.1177/0333102419828967
17	30.	Ware JH, Harrington D, Hunter DJ, D'Agostino RB. Missing Data. N Engl J Med.
18		2012;367(14):1353-1354. doi:10.1056/NEJMsm1210043
19	31.	Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the
20		what, why, when and how. BMC Med Res Methodol. 2013;13:92. doi:10.1186/1471-2288-13-92
21	32.	Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with missing
22		continuous outcome data using controlled multiple imputation: A practical guide. Stat Med.
23		2020;39(21):2815-2842. doi:10.1002/sim.8569
24	33.	Marcotte TD, Umlauf A, Grelotti DJ, et al. Driving Performance and Cannabis Users' Perception of
25		Safety: A Randomized Clinical Trial. JAMA psychiatry. 2022;79(3):201-209.
26		doi:10.1001/jamapsychiatry.2021.4037
27	34.	Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric
28		modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790-4805.

1 doi:10.1111/ppn.13250	1	doi:10.1111/bph.13250
-------------------------	---	-----------------------

- 2 35. Pertwee RG, Ross RA, Craib SJ, Thomas A. (-)-Cannabidiol antagonizes cannabinoid receptor
- 3 agonists and noradrenaline in the mouse vas deferens. *Eur J Pharmacol*. 2002;456(1-3):99-106.
- 4 doi:10.1016/s0014-2999(02)02624-9
- 5 36. Schubart CD, Sommer IEC, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MPM. Cannabis with
- 6 high cannabidiol content is associated with fewer psychotic experiences. *Schizophr Res.*
- 7 2011;130(1-3):216-221. doi:10.1016/j.schres.2011.04.017
- 8 37. Sallan SE, Zinberg NE, Frei E. Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients
- 9 Receiving Cancer Chemotherapy. *N Engl J Med.* 1975;293(16):795-797.
- 10 doi:10.1056/NEJM197510162931603
- 11 38. U.S. Department of Health and Human Services: Food and Drug Administration. *Migraine:*
- 12 Developing Drugs for Acute Treatment- Guidance for Industry.; 2018.
- 13 https://www.fda.gov/downloads/drugs/guidances/ucm419465.pdf.
- 14 39. Okusanya BO, Lott BE, Ehiri J, McClelland J, Rosales C. Medical Cannabis for the Treatment of
- 15 Migraine in Adults: A Review of the Evidence. *Front Neurol*. 2022;13:871187.
- 16 doi:10.3389/FNEUR.2022.871187/FULL